FindTrial
Sign In

To study the comparative effect of bhilvaphaladi churnavati and kallingadi churnavati in the management of grahani.

A Comparative Clinical Study of Bhilvaphaladichurnavati and KallingadichurnaVati in Management of Grahani

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/10/037513
Enrollment
60
Registered
2021-10-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K929- Disease of digestive system, unspecified

Interventions

Intervention1: Bhilvaphaladichurnavati: Group A 30 patients will be treated with Bhilvaphaladichurnavati 250 mg two tablets twice a day orally for 45 days Control Intervention1: Bhilvaphaladichurnava

Sponsors

PDEAs College of Ayurveda And Research Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i. After Screening for Covid 19 in Covid screening Patients will be Selected ii. Granthokta Sign and Symptoms of Grahani iii. Age 18 to 65 years irrespective of Gender

Exclusion criteria

Exclusion criteria: i. Known case of Tuberculosis, Cancer of Stomach, Cancer of Esophagus, Stomach Ulcer, Ulcerative Colitis, Acute Diarrhea, Intestinal Tuberculosis, HIV,etc. Presence of Occult Blood in Stool. ii. Pregnancy and Lactating woman iii. Patients with any surgery of Gastro intestinal tract.

Design outcomes

Primary

MeasureTime frame
Primary outcome would be base on grading parameter of Annavah SrotasTimepoint: Follow up every 15th days for 3 times—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Mahesh Pandit Kore

PDEAs College of Ayurved and Research Centre Akurdi Pune

khobragaderupali19@gmail.com8378929859

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026